Questions on accounting for OID in BS adjustments and asset capitalization

Should you account for OID by netting it against the par value of the debt (so if company does LBO with 500M in term loan and OID of 6M, then record 494M in debt incurred) or can I record it as a capitalized asset the same way as you would with financing fees?

Also, Im in general confused about what a capitalized asset is and when to record an item as capitalized asset vs. expense. Isn't financing fees a one-time expense so why isnt it taken out of retained capital the same way it is for advisory fees?

I know in tech start-ups, the term capitalized R&D comes up frequently, but I don't know when a company would choose to capitalize its R&D vs. report it on the IS as regular R&D. Is it just to inflate NI given that R&D likely makes up a big chunk of expenses for a tech start-up? But it would also result in a huge dip in FCF since capitalized assets must be included in the calculation given that they are cash spends right?

3 Comments
 
Most Helpful

Should you account for OID by netting it against the par value of the debt (so if company does LBO with 500M in term loan and OID of 6M, then record 494M in debt incurred) or can I record it as a capitalized asset the same way as you would with financing fees? i think either would get you to same result but former (treating it as contraliability) is how it works in real life

Also, Im in general confused about what a capitalized asset is and when to record an item as capitalized asset vs. expense. Isn't financing fees a one-time expense so why isnt it taken out of retained capital the same way it is for advisory fees? Same reason capex isn't taken out as a one time hit - you get the benefit of financing over the life of the loan, so you should amortize the cost of obtaining it over the same time horizon to better reflect economic reality

I know in tech start-ups, the term capitalized R&D comes up frequently, but I don't know when a company would choose to capitalize its R&D vs. report it on the IS as regular R&D. Is it just to inflate NI given that R&D likely makes up a big chunk of expenses for a tech start-up? But it would also result in a huge dip in FCF since capitalized assets must be included in the calculation given that they are cash spends right? if you capitalize R&D you amortize its value over time so you're not really inflating anything, you're deferring recognition of it over its useful life

 

thanks for clearing up my questions. My point on R&D isnt that it is inflating any financial performance persay, but that theres a big difference between IS and CF because it is capitalized. Am i correct on that capitalized assets must be adjusted for in FCF (cash flow from investing activities)?

 

Nam est voluptates unde beatae aut ratione accusantium. Rerum eveniet illo minus in. Eveniet ipsam dolorem voluptas deleniti amet sapiente facilis itaque. Inventore dolorem neque sapiente et. Velit minus ullam ducimus architecto sed doloremque nemo. Eos eum magni enim sed quia quia ea maiores.

Fuga aperiam iusto occaecati consequatur ut impedit. Voluptas impedit veritatis maxime debitis distinctio. Quos consequatur voluptatem rerum maiores id qui delectus aperiam. Voluptate error labore perspiciatis aliquam animi.

Quo praesentium et cumque consequuntur. Corrupti iure sapiente omnis dolorem rerum iste libero. Vel aliquid rerum asperiores libero mollitia.

Aut quas autem qui corporis. Sint quas molestiae alias sit non impedit.

Career Advancement Opportunities

November 2026 Private Equity

  • Blackstone Group 99.6%
  • The Riverside Company 99.3%
  • KKR (Kohlberg Kravis Roberts) 98.9%
  • Warburg Pincus 98.5%
  • Vista Equity Partners 98.2%

Overall Employee Satisfaction

November 2026 Private Equity

  • Blackstone Group 99.6%
  • KKR (Kohlberg Kravis Roberts) 99.3%
  • The Riverside Company 98.9%
  • Ardian 98.5%
  • Warburg Pincus 98.1%

Professional Growth Opportunities

November 2026 Private Equity

  • Bain Capital 99.6%
  • Blackstone Group 99.3%
  • The Riverside Company 98.9%
  • Starwood Capital Group 98.5%
  • KKR (Kohlberg Kravis Roberts) 98.2%

Total Avg Compensation

November 2026 Private Equity

  • Principal (9) $653
  • Director/MD (24) $547
  • Vice President (100) $364
  • 3rd+ Year Associate (106) $280
  • 2nd Year Associate (236) $272
  • 1st Year Associate (414) $231
  • 3rd+ Year Analyst (33) $157
  • 2nd Year Analyst (97) $134
  • 1st Year Analyst (274) $126
  • Intern/Summer Associate (40) $79
  • Intern/Summer Analyst (357) $61
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”